Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Oncology (Williston Park, N.Y.)|May 22, 2013
Advanced urothelial carcinoma: moving the field forwardMatthew I Milowsky
The New England Journal of Medicine|November 13, 2024
Toward Curing More Patients with Bladder Cancer - A New Perioperative StrategyMatthew I Milowsky
Urologic Oncology|January 31, 2012
Fibroblast growth factor receptor-3 in urothelial tumorigenesisGopa Iyer, Matthew I Milowsky
Cancer|September 15, 2016
Reply to vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy eraTracy L Rose, Matthew I Milowsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Is extending surveillance guidelines for renal cell carcinoma without understanding patient outcomes putting the cart before the horse?Angela B Smith, Matthew I Milowsky
Cancer|March 26, 2020
Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancerChelsea K Osterman, Matthew I Milowsky
F1000Research|September 28, 2020
New and Emerging Therapies in the Management of Bladder CancerChelsea K Osterman, Matthew I Milowsky
The Urologic Clinics of North America|April 18, 2015
Multidisciplinary care of the urothelial cancer patientArjun V Balar, Matthew I Milowsky
Current Oncology Reports|March 18, 2016
Improving Systemic Chemotherapy for Bladder CancerTracy L Rose, Matthew I Milowsky
The Lancet. Oncology|January 14, 2017
Checkpoint inhibition: a new beginning for urothelial cancerTracy L Rose, Matthew I Milowsky
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Oncology (Williston Park, N.Y.)|May 22, 2013
Advanced urothelial carcinoma: moving the field forwardMatthew I Milowsky
The New England Journal of Medicine|November 13, 2024
Toward Curing More Patients with Bladder Cancer - A New Perioperative StrategyMatthew I Milowsky
Urologic Oncology|January 31, 2012
Fibroblast growth factor receptor-3 in urothelial tumorigenesisGopa Iyer, Matthew I Milowsky
Cancer|September 15, 2016
Reply to vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy eraTracy L Rose, Matthew I Milowsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Is extending surveillance guidelines for renal cell carcinoma without understanding patient outcomes putting the cart before the horse?Angela B Smith, Matthew I Milowsky
Cancer|March 26, 2020
Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancerChelsea K Osterman, Matthew I Milowsky
F1000Research|September 28, 2020
New and Emerging Therapies in the Management of Bladder CancerChelsea K Osterman, Matthew I Milowsky
The Urologic Clinics of North America|April 18, 2015
Multidisciplinary care of the urothelial cancer patientArjun V Balar, Matthew I Milowsky
Current Oncology Reports|March 18, 2016
Improving Systemic Chemotherapy for Bladder CancerTracy L Rose, Matthew I Milowsky
The Lancet. Oncology|January 14, 2017
Checkpoint inhibition: a new beginning for urothelial cancerTracy L Rose, Matthew I Milowsky
Pageof 21